MW: 423.89. Terazosin (TZ) which is marketed as an alpha1-adrenergic receptor antagonist, has been shown to alleviate organ damaged and increase survival in rodent models of sepsis and stroke in vivo (1). It inhibits apoptosis in macrophages by activation of Pgk1 and Hsp90 (1).